ZEVRA THERAPEUTICS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2014 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Zevra Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2014 to Q3 2024.
  • Zevra Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$33.2M, a 220% decline year-over-year.
  • Zevra Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$89.7M, a 339% decline year-over-year.
  • Zevra Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$46M, a 72% decline from 2022.
  • Zevra Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$26.8M, a 213% decline from 2021.
  • Zevra Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$8.56M, a 33% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$89.7M -$33.2M -$22.9M -220% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$66.8M -$19.9M -$17.4M -674% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-13
Q1 2024 -$49.5M -$16.6M -$3.41M -25.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-13
Q4 2023 -$46M -$19.9M -$25.6M -446% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-01
Q3 2023 -$20.4M -$10.4M -$3.75M -56.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$16.7M -$2.57M +$21.5M +89.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-13
Q1 2023 -$38.1M -$13.2M -$11.4M -609% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-13
Q4 2022 -$26.8M $5.75M +$8.45M Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 -$35.2M -$6.62M -$4.86M -276% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$30.4M -$24M -$30.2M -488% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-07
Q1 2022 -$123K -$1.86M +$8.43M +81.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-07
Q4 2021 -$8.56M -$2.7M +$2.15M +44.3% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-07
Q3 2021 -$10.7M -$1.76M +$1.25M +41.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$12M $6.2M +$5.34M +622% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$17.3M -$10.3M -$4.54M -78.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$12.8M -$4.86M +$1.18M +19.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$13.9M -$3.01M -$6.07M -198% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$7.87M $859K +$10.1M Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$18M -$5.75M +$6.54M +53.2% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
Q4 2019 -$24.5M -$6.04M -$854K -16.5% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-12
Q3 2019 -$23.7M $3.06M +$18.1M Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-30
Q2 2019 -$41.8M -$9.26M +$736K +7.37% Apr 1, 2019 Jun 30, 2019 10-Q 2020-10-30
Q1 2019 -$42.5M -$12.3M +$13.9M +53.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-10-30
Q4 2018 -$56.5M -$5.18M +$5.38M +50.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-28
Q3 2018 -$61.8M -$15.1M -$5.09M -51% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$56.8M -$9.99M -$3.48M -53.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-14
Q1 2018 -$53.3M -$26.2M -$9.9M -60.6% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-14
Q4 2017 -$43.4M -$10.6M -$630K -6.34% Oct 1, 2017 Dec 31, 2017 10-K 2018-03-30
Q3 2017 -$42.8M -$9.98M +$3.43M +25.6% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 -$46.2M -$6.52M -$16.3M -167% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-10
Q1 2017 -$29.9M -$16.3M -$13.4M -456% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-11
Q4 2016 -$16.5M -$9.94M -$733K -7.97% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-30
Q3 2016 -$15.8M -$13.4M -$3.67M -37.7% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-30
Q2 2016 -$12.1M $9.77M +$39.5M Apr 1, 2016 Jun 30, 2016 10-K 2018-03-30
Q1 2016 -$51.6M -$2.93M +$3.04M +50.9% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-30
Q4 2015 -$54.7M -$9.2M +$2.64M +22.3% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-10
Q3 2015 -$57.3M -$9.74M -$2.61M -36.5% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-10
Q2 2015 -$54.7M -$29.7M -$26.2M -733% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-10
Q1 2015 -$28.5M -$5.97M -$4.07M -214% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-10
Q4 2014 -$24.5M -$11.8M Oct 1, 2014 Dec 31, 2014 10-K 2016-03-16
Q3 2014 -$7.14M Jul 1, 2014 Sep 30, 2014 10-K 2016-03-16
Q2 2014 -$3.57M Apr 1, 2014 Jun 30, 2014 10-K 2016-03-16
Q1 2014 -$1.91M Jan 1, 2014 Mar 31, 2014 10-K 2016-03-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.